Epigenetic drugs in the treatment of skeletal muscle atrophy

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 3, 2008, Pages 233-241

  Guasconi, Valentina ^a   Puri, Pier Lorenzo ^a,b  

^a DULBECCO TELETHON INSTITUTE   (Italy)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Autophagy; Cachexia; Chromatin; Deacetylase inhibitors; Muscle atrophy; Sarcopenia

Indexed keywords

DEACETYLASE INHIBITOR; ENZYME INHIBITOR; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG;

AUTOPHAGY; CACHEXIA; CATABOLISM; CHRONIC DISEASE; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME DEGRADATION; EPIGENETICS; HUMAN; MUSCLE ATROPHY; MUSCLE MASS; PATHOGENESIS; REVIEW;

EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 42149098394     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3282fa1810     Document Type: Review

References (117)

1. Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 2003; 5:87-90.
2. Jagoe RT, Goldberg AL. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 2001; 4:183-190.
3. Goldspink DF, Garlick PJ, McNurlan MA. Protein turnover measured in vivo and in vitro in muscles undergoing compensatory growth and subsequent denervation atrophy. Biochem J 1983; 210:89-98.
4. Musarò A, McCullagh K, Paul A, Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001; 27:195-200.
5. DeVol DL, Rotwein P, Sadow JL, et al. Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth. Am J Physiol 1990; 259 (1 Pt 1):E89-95.
6. Philippou A, Maridaki M, Halapas A, Koutsilieris M. The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo 2007; 21:45-54.
7. Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001; 3:1014-1019.
8. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001; 3:1009-1013.
9. Scott PH, Brunn GJ, Kohn AD, et al. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci USA 1998; 95:7772-7777.
10. von Manteuffel SR, Gingras AC, Ming XF, et al. 4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. Proc Natl Acad Sci USA 1996; 93:4076-4080.
11. Hara K, Yonezawa K, Kozlowski MT, et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 1997; 272:26457-26463.
12. Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-789.
13. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117:399-412.
14. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14:395-403.
15. Horsley V, Pavlath GK. NFAT: ubiquitous regulator of cell differentiation and adaptation. J Cell Biol 2002; 156:771-774.
16. Musarò A, McCullagh KJ, Naya FJ, et al. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 1999; 400:581-585.
17. 2+-dependent calcineurin signalling pathway. Nature 1999; 400:576-581.
18. Moelling K, Schad K, Bosse M, et al. Regulation of Raf-Akt cross-talk. J Biol Chem 2002; 277:31099-31106.
19. Rommel C, Clarke BA, Zimmermann S, et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999; 286:1738-1741.
20. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999; 286:1741-1744.
21. Serra C, Palacios D, Mozzetta C, et al. Functional interdependence at the chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle differentiation. Mol Cell 2007; 28:200-213. This manuscript reveals an essential role of inflammation-activated MKK6-p38 and the IGF1-induced PI3K/AKT pathways in the assembly of the muscle transcriptosome, by targeting distinct components at the chromatin level.
22. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997; 387:83-90.
23. Langley B, Thomas M, Bishop A, et al. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem 2002; 277:49831-49840.
24. Grobet L, Martin LJ, Poncelet D, et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 1997; 17:71-74.
25. Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004; 350:2682-2688.
26. Mosher DS, Quignon P, Bustamante CD, et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 2007; 3:e79. This paper describes a myostatin mutation found in a dog breed resulting in a double-muscled phenotype.
27. Amthor H, Nicholas G, McKinnell I, et al. Follistatin complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis. Dev Biol 2004; 270:19-30.
28. Zimmers TA, Davies MV, Koniaris LG, et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002; 296:1486-1488.
29. Luo D, Renault VM, Rando TA. The regulation of Notch signaling in muscle stem cell activation and postnatal myogenesis. Semin Cell Dev Biol 2005; 16:612-622.
30. Kitzmann M, Bonnieu A, Duret C, et al. Inhibition of Notch signaling induces myotube hypertrophy by recruiting a subpopulation of reserve cells. J Cell Physiol 2006; 208:538-548.
31. Horsley V, Jansen KM, Mills ST, Pavlath GK. IL-4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell 2003; 113:483-494.
32. Solomon AM, Bouloux PM. Modifying muscle mass: the endocrine perspective. J Endocrinol 2006; 2:349-360.
33. Attaix D, Ventadour S, Codran A, et al. The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem 2005; 41:173-186.
34. Tawa NE Jr, Odessey R, Goldberg AL. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J Clin Invest 1997; 100:197-203.
35. Lecker SH, Jagoe RT, Gilbert A, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004; 18:39-51.
36. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294:1704-1708.
37. Gomes MD, Lecker SH, Jagoe RT, et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001; 98:14440-14445.
38. Centner T, Yano J, Kimura E, et al. Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J Mol Biol 2001; 306:717-726.
39. Kedar V, McDonough H, Arya R, et al. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc Natl Acad Sci USA 2004; 101:18135-18140.
40. Clarke BA, Drujan D, Willis MS, et al. The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab 2007; 6:376-385. Identification of the mechanism by which myosin heavy chain is degraded under atrophy conditions.
41. Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 2004; 287:E591-E601.
42. Kamei Y, Miura S, Suzuki M, Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 2004; 279:41114-41123.
43. Hasselgren P. Ubiquitination, phosphorylation, and acetylation: triple threat in muscle wasting. J Cell Physiol 2007; 213:679-689. Interesting review underscoring the role of posttranslational modifications of proteins involved in muscle atrophy and in the modulation of their activity.
44. Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 1985; 135:3972-3977.
45. Langen RC, Schols AM, Kelders MC, et al. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J 2001; 15:1169-1180.
46. Cai D, Frantz JD, Tawa NE Jr, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004; 119:285-298.
47. Mourkioti F, Kratsios P, Luedde T, et al. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J Clin Invest 2006; 116:2945-2954.
48. Guttridge DC, Mayo MW, Madrid LV, et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289:2363-2366.
49. Li YP, Chen Y, John J, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005; 19:362-370.
50. Agust́ A, Morlá M, Sauleda J, et al. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 2004; 59:483-487.
51. Suzuki N, Motohashi N, Uezumi A, et al. NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS. J Clin Invest 2007; 117:2468-2476. Involvement of nNOS/NO in the regulation of FOXO in muscle atrophy.
52. Ma K, Mallidis C, Artaza J, et al. Characterization of 5′-regulatory region of human myostatin gene: regulation by dexamethasone in vitro. Am J Physiol Endocrinol Metab 2001; 281:E1128-E1136.
53. Gilson H, Schakman O, Combaret L, et al. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 2007; 148:452-460. This paper suggests an important role of myostatin in muscle atrophy caused by glucocorticoids.
54. Allen DL, Unterman TG. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am J Physiol Cell Physiol 2007; 292:C188-C199. Role of FOXO1 and SMAD transcription factors in the regulation of myostatin the expression.
55. Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr 2007; 26:389-399. Review examining how different forms of atrophy are linked.
56. Stevenson EJ, Giresi PG, Koncarevic A, Kandarian SC. Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle. J Physiol 2003; 551 (Pt 1):33-48.
57. Reid MB. Response of the ubiquitin-proteasome pathway to changes in muscle activity. Am J Physiol Regul Integr Comp Physiol 2005; 288:R1423-R1431.
58. Hunter RB, Stevenson E, Koncarevic A, et al. Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. FASEB J 2002; 16:529-538.
59. Hunter RB, Kandarian SC. Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J Clin Invest 2004; 114:1504-1511.
60. Li YP, Schwartz RJ, Waddell ID, et al. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J 1998; 12:871-880.
61. Furukawa-Hibi Y, Yoshida-Araki K, Ohta T, et al. FOXO forkhead transcription factors induce G(2)-M checkpoint in response to oxidative stress. J Biol Chem 2002; 277:26729-26732.
62. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr 1997; 127 (Suppl 5):990S-991S.
63. Juul A, Main K, Blum WF, et al. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 1994; 41:85-93.
64. Barton ER, Morris L, Musaro A, et al. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 2002; 157:137-148.
65. Butterfield GE, Thompson J, Rennie MJ, et al. Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women. Am J Physiol 1997; 272 (1 Pt 1):E94-E99.
66. Tenover JL. Experience with testosterone replacement in the elderly. [discussion S82]. Mayo Clin Proc 2000; (Suppl 75):S77-S81.
67. Sinha-Hikim I, Cornford M, Gaytan H, et al. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J Clin Endocrinol Metab 2006; 91:3024-3033.
68. Conboy IM, Rando TA. Aging, stem cells and tissue regeneration: lessons from muscle. Cell Cycle 2005; 4:407-410.
69. Conboy IM, Conboy MJ, Smythe GM, Rando TA. Notch-mediated restoration of regenerative potential to aged muscle. Science 2003; 302:1575-1577.
70. Conboy IM, Rando TA. The regulation of Notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis. Dev Cell 2002; 3:397-409.
71. Conboy IM, Conboy MJ, Wagers AJ, et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005; 433:760-764.
72. Lexell J, Taylor CC, Sjöström M. What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. J Neurol Sci 1988; 84:275-294.
73. Balagopal P, Schimke JC, Ades P, et al. Age effect on transcript levels and synthesis rate of muscle MHC and response to resistance exercise. Am J Physiol Endocrinol Metab 2001; 280:E203-E208.
74. Puigserver P. Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. Int J Obes (Lond) 2005; 29 (Suppl 1):S5-S9.
75. Lin J, Wu H, Tarr PT, et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002; 418:797-801.
76. Sandri M, Lin J, Handschin C, et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA 2006; 103:16260-16265.
77. McKinsey TA, Zhang CL, Olson EN. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci 2002; 27:40-47.
78. Dirks AJ, Hofer T, Marzetti E, et al. Mitochondrial DNA mutations, energy metabolism and apoptosis in aging muscle. Ageing Res Rev 2006; 5:179-195.
79. Dirks A, Leeuwenburgh C. Apoptosis in skeletal muscle with aging. Am J Physiol Regul Integr Comp Physiol 2002; 282:R519-R527.
80. Dargelos E, Brulé C, Combaret L, et al. Involvement of the calcium-dependent proteolytic system in skeletal muscle aging. Exp Gerontol 2007; 42:1088-1098. This paper presents evidence of the implication of calpains in sarcopenia.
81. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2:862-871.
82. Frost RA, Lang CH. Skeletal muscle cytokines: regulation by pathogen-associated molecules and catabolic hormones. Curr Opin Clin Nutr Metab Care 2005; 8:255-263.
83. Li YP, Reid MB. Effect of tumor necrosis factor-alpha on skeletal muscle metabolism. Curr Opin Rheumatol 2001; 13:483-487.
84. Hasselgren PO, Wray C, Mammen J. Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem Biophys Res Commun 2002; 290:1-10.
85. Coletti D, Yang E, Marazzi G, Sassoon D. TNFalpha inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO J 2002; 21:631-642.
86. Schwarzkopf M, Coletti D, Sassoon D, Marazzi G. Muscle cachexia is regulated by a p53-PW1/Peg3-dependent pathway. Genes Dev 2006; 20:3440-3452.
87. Dasarathy S, Dodig M, Muc SM, et al. Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. Am J Physiol Gastrointest Liver Physiol 2004; 287:G1124-G1130.
88. Coletti D, Moresi V, Adamo S, et al. Tumor necrosis factor-alpha gene transfer induces cachexia and inhibits muscle regeneration. Genesis 2005; 43:120-128.
89. Acharyya S, Butchbach ME, Sahenk Z, et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 2005; 8:421-432.
90. Durbeej M, Campbell KP. Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr Opin Genet Dev 2002; 12:349-361.
91. Langenbach KJ, Rando TA. Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve 2002; 26:644-653.
92. Gregorevic P, Allen JM, Minami E, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006; 12:787-789.
93. Grozdanovic Z, Gosztonyi G, Gossrau R. Nitric oxide synthase I (NOS-I) is deficient in the sarcolemma of striated muscle fibers in patients with Duchenne muscular dystrophy, suggesting an association with dystrophin. Acta Histochem 1996; 98:61-69.
94. Crosbie RH, Barresi R, Campbell KP. Loss of sarcolemma nNOS in sarcoglycan-deficient muscle. FASEB J 2002; 16:1786-1791.
95. Mizushima N. Autophagy: process and function. Genes Dev 2007; 21:2861-2873. Review describing the process of autophagy and its role in cell metabolism.
96. Mizushima N. The pleiotropic role of autophagy: from protein metabolism to bactericide. Cell Death Differ 2005; 12 (Suppl 2):1535-1541.
97. Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 2005; 6:439-448.
98. Hesselink RP, Wagenmakers AJ, Drost MR, et al. Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II. Biochim Biophys Acta 2003; 1637:164-170.
99. Nishino I, Fu J, Tanji K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000; 406:906-910.
100. Nishino I. Autophagic vacuolar myopathy. Semin Pediatr Neurol 2006; 13:90-95.
101. Bechet D, Tassa A, Taillandier D, et al. Lysosomal proteolysis in skeletal muscle. Int J Biochem Cell Biol 2005; 37:2098-2114.
102. Sacheck JM, Hyatt JP, Raffaello A, et al. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J 2007; 21:140-155. This paper shows that the atrophy associated with systemic catabolic states and following disuse involves the induction of similar transcription patterns.
103. Juhász G, Puskás LG, Komonyi O, et al. Gene expression profiling identifies FKBP39 as an inhibitor of autophagy in larval Drosophila fat body. Cell Death Differ 2007; 14:1181-1190. Evidence of the role of FOXO in modulating autophagy in Drosophila.
104. Mammucari C, Milan G, Romanello V, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007; 6:458-471.
105. Zhao J, Brault JJ, Schild A, et al. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 2007; 6:472-483. These two papers demonstrate the involvement of autophagy in muscle atrophy, and most importantly, define FOXO as a key mediator of both proteolysis and autophagy.
106. Tatar M, Bartke A, Antebi A. The endocrine regulation of aging by insulin-like signals. Science 2003; 299:1346-1351.
107. Murphy CT, McCarroll SA, Bargmann CI, et al. Genes that act downstream of DAF-16 to influence the lifespan of caenorhabditis elegans. Nature 2003; 424:277-283.
108. Berdichevsky A, Viswanathan M, Horvitz HR, Guarente L. C. elegans SIR-2.1 interacts with 14-3-3 proteins to activate DAF-16 and extend life span. Cell 2006; 125:1165-1177.
109. Meléndez A, Tallóczy Z, Seaman M, et al. Autophagy genes are essential for dauer development and life-span extension in C. elegans. Science 2003; 301:1387-1391.
110. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 1:38-45.
111. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in drosophila. Nature 2001; 413:739-744.
112. Minamiyama M, Katsuno M, Adachi H, et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2004; 11:1183-1192.
113. Elaut G, Rogiers V, Vanhaecke T. The pharmaceutical potential of histone deacetylase inhibitors. Curr Pharm Des 2007; 13:2584-2662. Review on the pharmacological relevance of the use of histone deacetylase inhibitors in the treatment of human disorders.
114. Minetti GC, Colussi C, Adami R, et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 2006; 10:1147-1155.
115. Iezzi S, Cossu G, Nervi C, et al. Stage-specific modulation of skeletal myogenesis by inhibitors of nuclear deacetylases. Proc Natl Acad Sci USA 2002; 11:7757-7766.
116. Iezzi S, Di Padova M, Serra C, et al. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell 2004; 5:673-684.
117. Liu Y, Denlinger CE, Rundall BK, et al. Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. J Biol Chem 2006; 281:31359-31368.